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Abstract 
BACKGROUND: Colorectal cancer is one of the most common and deadly cancers, particularly 
in persons greater than 50 years of age.  Most colorectal malignancies are slow-growing, making 
regular screening increasingly important to decrease morbidity, mortality, and cost of treatment. 
Cologuard® serves as an effective and non-invasive colorectal cancer screening modality for 
average-risk adults. 
PURPOSE: The purpose of this study was to evaluate the impact of a provider-based educational 
intervention on the knowledge, attitudes, self-efficacy, and ordering rates of Cologuard® among 
primary care providers. 
METHODS: This study was a single-center, pre/post implementation study of the effectiveness 
of a provider-based educational intervention using a validated resource tool from the American 
Cancer Society.  The first stage of the project featured a pre/post-test examination of the 
knowledge, attitudes, and self-efficacy related to Cologuard® of 14 primary care providers 
before and after an educational intervention for providers in November 2018.  The second stage 
of the project included a separate pre/post-test design to determine the effect of the educational 
intervention on provider order rates of Cologuard® using 200 randomly selected charts prior to 
the intervention during the months of August through October 2018, and 200 randomly selected 
charts after the intervention during the months of December 2018 through February 2019 for 
patients meeting screening qualifications. 
RESULTS:  Of the 18 providers who attended the educational program, 14 completed and 
returned pre- and post- tests.  There was a statistically significant increase in provider knowledge 
(p<0.001) and self-efficacy (p=0.002) from the pre- to post- intervention periods.  There was no 
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statistically significant difference in attitudes (p=0.142) or Cologuard® order rates (p=0.660) 
from the pre- to post- intervention periods.  
CONCLUSION: Provider-based educational programs serve as an effective intervention to 
address certain measures in practice.  Increases in provider knowledge and self-efficacy related 
to Cologuard® were seen in the post-intervention period, and while there was not a statistically 
significant difference in provider attitudes, it is important to note an increase on the measurement 
scale did occur.  Future implications for practice may involve alternate solutions to improving 
Cologuard® order rates, though this initiative may provide necessary first-steps to facilitate 
organizational changes that would lead to an increase in Cologuard® orders. 
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The Effect of a Provider-Based Educational Program on Knowledge, Attitudes, Self-Efficacy, 
and Order Rates of Cologuard® in a Primary Care Clinic 
Introduction 
In the United States, colorectal cancer (CRC) is the third most prevalent cancer and 
second deadliest cancer, with 139,992 new cases diagnosed and 51,651 deaths occurring in 2014 
(Centers for Disease Control and Prevention [CDC], 2017b).  Most colorectal malignancies are 
slow-growing, making regular screening important in decreasing morbidity and mortality.  
According to the American Cancer Society (ACS), preventive screening and early detection of 
pre-cancerous or cancerous growths greatly improve survival rates and decrease costs associated 
with long-term treatment (2014).  The U.S. Preventive Services Task Force (USPSTF) has issued 
a Grade A recommendation for CRC screening to begin at age 50 for average-risk adults, 
continue until age 75, and incorporate methods such as fecal occult blood testing, 
sigmoidoscopy, or colonoscopy (2015).   
Although CRC screening rates are on the rise, an opportunity exists for providers to 
better screen patients and discuss available screening options, thereby increasing screening 
uptake rates and improving overall outcomes.  Providers play a pivotal role in decreasing CRC 
by recommending screening to eligible patients.  Provider recommendations are one of the main 
determinants in predicting the utilization of preventive services (Atassi, 2012).   
While colonoscopy remains the gold standard among CRC screening modalities, patients 
may have an aversion to this procedure or would prefer less invasive options.  Cologuard®, the 
only single-test screening modality available in the U.S. to combine a multi-target stool DNA 
test with fecal immunochemical testing (FIT), serves as an effective method to detect adenomas 
and CRC for patients preferring alternative screening options (ACS, 2017a).  The purpose of this 
3 
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project was to determine the effectiveness of a provider-based educational intervention on the 
knowledge, beliefs, self-efficacy, and ordering rates of Cologuard® in a primary care clinic.  
Background 
In 2015, approximately 774,000 deaths worldwide resulted from CRC (World Health 
Organization [WHO], 2018).  Of those who develop colorectal malignancies, 90% are in persons 
50 years and older (ACS, 2014).  In the U.S., morbidity and mortality due to CRC far exceeds 
most other cancers (CDC, 2017b).  Kentucky’s CRC incidence rates rank among the highest in 
the nation, with an incidence rate of 49.4 per 100,000 persons and fatality rate of 17 per 100,000 
persons in 2014 (CDC, 2017a). 
Screening Recommendations 
CRC screening is defined by the American College of Gastroenterology (ACG) as the 
process by which early-stage cancers and pre-cancerous growths are detected in asymptomatic 
persons without previous history of malignancy or pre-cancerous cells (Rex et al., 2017).  The 
CDC (2019) and USPSTF (2015) recommend the screening process begin at age 50 through age 
75 for all persons with average-risk of developing CRC using colonoscopy, flexible 
sigmoidoscopy, or stool-based tests.  These two organizations suggest providers use special 
clinical consideration for CRC screening in African Americans, but maintain age 50 as an 
appropriate age to begin screening (Williams, 2016).  With evidence to suggest that CRC 
incidence and mortality is greater in African Americans, the ACG recommends screening in this 
patient population to begin at age 45 (Rex et al., 2017).   In 2018, the ACS updated their 
recommendations for average-risk adults of any racial or ethnic group to begin screening at age 
45 and end at age 75 or a projected life expectancy of more than ten years beyond age 75 (ACS, 
2018).   
4 
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When discussing CRC screening with patients, it is important for the provider to be 
aware of evidence-based clinical recommendations. Exceptions for ‘average-risk’ persons 
include the following: 
a) Symptomatic (experiencing signs or symptoms of potential colorectal disease, 
including but not limited to: lower abdominal pain, bloody stools, positive guaiac or 
FIT test) 
b) Personal history of CRC or adenomatous polyps 
c) Family history of CRC (first-degree relative with CRC or advanced adenoma 
diagnosed <60 years of age OR two first-degree relatives with CRC or advanced 
adenoma) 
d) Personal history of inflammatory bowel disease (such as Crohn’s disease or ulcerative 
colitis) 
e) Hereditary colorectal cancer syndrome (such as familial adenomatous polyposis 
[FAP] or Lynch syndrome) 
f) Personal history of radiation to the abdomen or pelvis 
g) Personal history of surgical CRC resection 
(Centers for Medicare and Medicaid Services [CMS], 2014; Rex et al., 2017; USPSTF, 
2015).  
Persons at greater-risk for developing CRC should consult with their healthcare provider 
about screening recommendations, including age to begin screening, appropriate screening 
strategy, and follow-up intervals.   
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Screening Modalities 
Joint guidelines separate CRC screening options into cancer prevention tests and cancer 
detection tests.  Colorectal cancer prevention tests are preferred and should be offered first, due 
to the ability to directly visualize the colon and capture imaging of malignancies or polyps.  
While CRC detection tests have lower sensitivity for polyps and malignancies compared to 
imaging tests, these options are validated for their use in practice and should be offered to 
patients who decline colonoscopy or other CRC prevention tests (Rex et al., 2017).  A positive 
(or abnormal) screening result from any CRC detection test requires a follow-up colonoscopy to 
further investigate.  It is important to note that older guaiac-based fecal occult blood testing 
should not be used for screening.  CRC screening recommendations of the most commonly used 
modalities are summarized in Table 1.   
Cologuard® 
Although CRC prevention tests—such as colonoscopy or flexible sigmoidoscopy—are 
the preferred screening modality, early detection tests are widely used and play an important role 
in CRC screening (Rex et al., 2017).  Many patients have an aversion to invasive exams, or have 
issues with accessibility or availability in regards to medical procedures.   Evidence from the 
ACS suggests a large proportion of patients, when given the choice of invasive exam versus 
stool-based tests, prefer the less invasive option (2017a).  Additionally, modeling studies propose 
that outcomes of high-quality stool-based screening tests are nearly comparable to colonoscopies 
when strict adherence to screening intervals and appropriate follow-up occur (ACS, 2017a).   
Deoxyribonucleic acid (DNA) biomarkers are shed into the stool as colorectal cancers 
grow and adenomas degenerate.  Cologuard®, the only single-test screening modality available 
in the U.S. to combine FIT with a multi-target stool DNA test, serves as an effective method to 
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detect even trace amounts of these molecular markers for CRC and pre-cancerous neoplasias 
(ACS, 2017a).  Because Cologuard® is a fairly new test, with Food and Drug Administration 
(FDA) approval just within the past five years, technology and data about this modality are still 
evolving.  However, data across numerous organizations and studies reveals a pattern of much 
higher sensitivity compared to all other stool-based tests (Song & Li, 2016; ACS, 2017a). 
One systematic review of several large randomized-controlled trials reveals Cologuard® 
as 92.3% sensitive in detecting CRC, whereas FIT testing alone averaged a sensitivity of 73.8% 
(Song & Li, 2016).  These numbers vary only slightly when compared to figures from studies 
published by the ACS.  Cologuard® proved to be much less specific, however, than its FIT 
screening counterpart.  The same literature review conducted by Song and Li (2016) revealed 
specificity of 86.6% for Cologuard®, and specificity of 94.9% for FIT testing; these percentages 
are akin to those distributed by the ACS.  A positive test result warrants follow-up with a 
colonoscopy.  Repeat screening with Cologuard® is recommended every three years for patients 
with a negative screening result. 
Cologuard® is a favorable test for patients preferring alternative screening options, as it 
is safe, commonly used in primary practice, and is covered by most insurers, including Medicare 
and Medicaid in the state of Kentucky (CMS, 2014).  Unlike many other stool-based tests, results 
from Cologuard® are not affected by medication or food, and require only a single bowel 
movement to complete screening (ACS, 2017a).  For patients who choose Cologuard®, the 
screening kit is mailed directly to the patient’s home, contains directions in English and Spanish 
with the kit, and includes a pre-addressed, pre-paid box for shipping the sample directly to the 
Direct Sciences lab once a patient collects it.  Patients facing lack of access to care, limited 
availability for bowel prep or travel, or who prefer less invasive modalities can benefit from 
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Cologuard®.  One main takeaway for providers is any screening is better than no screening, and 
providing the patient with screening options does improve screening uptake rates (ACS, 2017a).   
Provider Education to Impact Screening 
Provider-based interventions are one strategy that can be used to influence CRC 
screening rates.  A randomized controlled trial (RCT) by Lane, Messina, Cavanaugh, and Chen 
(2008) focused on provider education as an intervention to improve CRC screening and patient 
adherence to screening recommendations.  The intervention included a PowerPoint presentation 
of materials, interactive questionnaires, discussion of behavioral approaches, and distribution of 
educational resources to providers in the experimental group.  The control group did not receive 
the educational intervention.  The results of that study revealed a statistically significant increase 
in patient self-reports of providers recommending CRC screening in the intervention cohort 
compared to the control group (p=0.04).  Additionally, short and long term improvement in 
completion of CRC screening occurred among patients seen by providers in the experimental 
group, including a 16% increase from baseline screening rates after 1 year (p<0.001) (Lane, 
Messina, Cavanaugh, & Chen, 2008).   
Another RCT in Appalachian Kentucky used academic detailing—an educational 
outreach method whereby trained healthcare professionals travel to practice sites to deliver 
evidence-based information to other healthcare workers—as the provider-based intervention 
(Dignan et al., 2014).  At the cessation of the study, colonoscopy orders increased for 
intervention sites that recommended CRC screening (p<0.01) (Dignan et al., 2014). 
One study by Sheinfeld-Gorin et al. (2000) used a pre- and post- test design to determine 
provider knowledge and identify potential screening barriers in an underserved urban 
community.  The investigators of this study selected a provider-based educational session, again 
8 
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using academic detailing, as the intervention.  The findings included a statistically significant 
difference in provider knowledge scores before and after the educational intervention (p<0.001) 
over an 18-month period.  Providers in the intervention group also reported significantly fewer 
barriers to screening practices in the post-test period than providers in the control group (p<0.05) 
(Sheinfeld-Gorin et al., 2000). 
A descriptive study by Rim et al. (2009) used surveys to examine the relationship 
between knowledge, attitudes, beliefs, and CRC screening practices of 109 healthcare 
professionals, including nurses and providers.  The results revealed a strong association between 
provider knowledge and higher CRC screening rates (p=0.02), but no statistically significant 
correlation between attitudes, beliefs, and CRC screening practices (Rim et al., 2009).  
Additionally, the CRC screening practices of individual providers had no statistically significant 
correlation to increased rates of patients screened. 
Addressing Barriers to Screening 
Screening for CRC has the potential to detect cancerous and pre-cancerous lesions at 
early stages, thereby improving long term survival rates.  Despite clinical recommendations, 
about one-third of adults ages 50-75 have not been screened for CRC (ACS, 2017a).  A recent 
study by the CDC revealed that underwhelming CRC screening rates may be attributed to patient 
evasion of tests because of bowel preparation, unfamiliarity about screening options, fear of 
invasiveness from colonoscopy, fear of complications, negative familial history, lack of 
symptoms, unawareness by the provider to screen, and absence of recommendation in general by 
the provider (Cooper & Gelb, 2016).  Additionally, disparities among minority populations, 
uninsured persons, and persons of lower income levels exist when evaluating CRC screening and 
follow-up screening (ACS, 2017a).  A literature review conducted by the ACG revealed one of 
9 
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the biggest disparities exists among African American populations, as socioeconomic and 
genetic factors likely influence lower CRC screening rates and higher instances of morbidity and 
mortality (Rex et al., 2017).  Men and women of all ethnicities and races can develop CRC, with 
slightly higher incidences in male populations; the risk of developing CRC increases after age 50 
for both genders (CDC, 2017b).   
Using a multiple-option approach, whereby the provider offers and discusses two or more 
screening tests to the patient, is a recommended strategy that the ACG suggests in order to 
encourage informed decision-making and increase CRC screening follow-through (Rex et al., 
2017).  Patients are more likely to embrace preventive health if the services are recommended by 
a healthcare provider (Atassi, 2012).   
Theoretical Framework 
In 1975, Icek Ajzen and Martin Fishbein began reviewing studies in an attempt to prove 
that intention, rather than attitude toward a particular behavior, was the driving cause behind the 
behavior.  With this assumption, the Theory of Reasoned Action (TRA) was formed in 
1980.  Ajzen and Fishbein’s TRA framework ascertained that behavior is voluntary and carried 
out upon intent at a certain time.  Intention, by definition, is a willing and purposeful drive 
behind a behavior and aids in predicting whether or not a person will participate in the given 
behavior (Ajzen & Fishbein, 1980). The TRA model pertained only to voluntary actions 
(volitional control).  Instances that lacked volitional or purposeful control threatened the validity 
of the TRA model, so the Theory of Reasoned Action was revised into the Theory of Planned 
Behavior (TPB), which is simply the TRA model plus the perceived behavioral control factor. 
Ajzen and Fishbein determined that intention to perform a behavior is determined by the 
following four paradigms: (a) attitude, which encompasses a person’s positive or negative 
10
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assessment of an action, (b) subjective norms, or the perceived expectation a person believes 
others have of a given behavior, (c) volitional control, which is simply the conscious decision to 
do or not do an action, and fourth, (d) behavioral control, defined as one’s perception of how 
easy or difficult a task will be.  
Attitudes  
The first of these factors is attitudes, which describe the value one places on a certain 
behavior and affect the odds of a person to perform that behavior (Ajzen & Fishbein, 1980).  For 
example, if a provider views CRC screening as beneficial, his or her attitude will be favorable 
and the likelihood of screening for CRC will be greater.  Adversely, if a provider views a 
behavior as negative, harmful, inconvenient, or not valuable, then it is less likely for that person 
to suggest the given behavior.   
One strategy that can be used to assess provider attitudes is a questionnaire using open-
ended responses or a measurement tool, such as the Likert scale.  If the questionnaire reveals 
positive provider attitudes, corroboration and assurance from other healthcare personnel can 
reinforce those beliefs.  After identifying providers who do not have a positive attitude toward 
CRC screening, it may be helpful to reiterate the risks of CRC, as well as benefits of regular 
screening with support from facts obtained from the CDC, USPSTF, and other organizations.  
Following the premise of the TRA/TPB model, a positive change in attitude will lead to 
increased screening behaviors by providers, which could ultimately impact screening uptake 
rates by patients.   
Subjective Norms  
The second factor influencing intention is subjective norms, which answers the question, 
“How do I think others feel about this behavior?”  This construct of the TRA/TPB model 
11 
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deals with the perceived notions of others, rather than explicit expectations (Ajzen & Fishbein, 
1980).  The understanding an individual has about whether referent groups will approve or 
disapprove of an action influences the probability of that individual to participate in a given 
behavior.  Examples of ‘referent individuals’ include friends, coworkers, role models, or anyone 
else who an individual aims to please.  Healthcare providers are among the most influential of 
the referent groups (Atassi, 2012).  
Using this construct of the TRA/TPB model, it can be inferred that a provider who 
believes people within the medical community place importance on CRC screening, has 
coworkers who utilize screening, or believes that society supports screening and surveillance, 
would have the intention of pleasing these groups of individuals by following screening 
recommendations.  On the contrary, if one did not feel that referent groups believed in and 
standardized the practice of CRC screening, he or she would be less likely to screen patients.  
Offering verbal support of screening, adhering to guidelines and specific practice sites’ 
recommendations for screening, and being a champion for CRC screening within the medical 
community are ways providers can act as referent individuals to other healthcare workers. 
Volitional Control  
Volitional control purports that one can freely and deliberately exercise the power to act 
upon a decision (Ajzen & Fishbein, 1980).  It is the third factor of the TRA/TPB model to 
influence intention.  Despite strong recommendations from evidence-based guidelines, the 
conscious decision to discuss, order, and refer screening is ultimately left up to the provider.  
Similarly, patients have the right to refuse medical services, thus exercising volitional control on 
the situation.  
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Behavioral Control  
Not all situations and environments allow for volition, especially when more than one 
outside factor or determinant is present.  Behavioral control, which is an assumption of ease 
versus difficulty of a behavior, is more useful in determining behaviors in low-volition 
circumstances (Gochman, 1997).  This construct deals with the perceived control over an action, 
rather than the actual ability of carrying out the action.   
For example, a provider with strong perceived control of screening may believe he or she 
has time to discuss screening, has resources readily available, or has an appropriate level of 
knowledge and understanding about CRC screening.  Based on the TRA/TBP theory, a provider 
who feels that CRC screening is without major challenges will have greater intent to carry out 
screening.  A healthcare professional with weak perceived control, however, might view CRC 
screening as an action that is unmanageable.  This provider might feel that screening is too 
cumbersome or cannot be achieved during a specific time period.  Assessing providers’ 
perceptions of screening barriers is one way to determine behavioral control and subsequently 
formulate solutions. 
Purpose 
The purpose of this project was to determine if a provider-based educational intervention 
would increase primary care providers’ (a) knowledge of current Cologuard® recommendations 
and procedures for use; (b) attitudes about Cologuard®; (c) self-efficacy of prescribing 
Cologuard®; and (d) ordering rates of Cologuard®.  This project was part of a larger quality 
improvement (QI) initiative in a large primary care clinic. 
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Methods 
Design 
This study was a single-center, pre/post implementation study of the effectiveness of a 
provider-based educational intervention using a validated resource tool from the ACS.  The first 
stage of the project featured a pre/post-test examination of the knowledge, attitudes, and self-
efficacy related to Cologuard® of 14 primary care providers before and after an educational 
intervention for providers in November 2018.  The second stage of the project included a 
separate pre/post-test design to determine the effect of the educational intervention on provider 
order rates of Cologuard® using 200 randomly selected charts prior to the intervention during 
the months of August through October 2018, and 200 randomly selected charts after the 
intervention during the months of December 2018 through February 2019 for patients meeting 
screening qualifications. 
Setting 
This project took place at a primary care clinic in central Kentucky.  This institution 
primarily serves residents of central Kentucky seeking an array of comprehensive services, 
including preventive medicine, screening, wellness exams, care for chronic conditions, and acute 
medical visits.  
Quality Improvement 
Several solutions exist to address the problem of subpar CRC screening rates, including 
patient-based interventions and processes aimed at provider or community health center practice 
improvement.  QI teams may provide valuable information to a clinic by conducting 
performance reviews, identifying weaknesses in practice, and creating/monitoring improvement 
processes (Agency for Healthcare Research and Quality [AHRQ], 2013).    
14 
EFFECT OF EDUCATIONAL PROGRAM RELATED TO COLOGUARD®  
2 
 
The preventative health QI team in the clinic included several interdisciplinary members 
from the areas of nursing, medicine, administration, and ancillary staff.  The goal of the QI team 
was to identify a problem within the clinic (underutilization of Cologuard®) and formulate 
processes (Plan-Do-Study-Act cycles) to change the problem (increase acceptance and order 
rates of Cologuard®).  Monthly team meetings were held to discuss progress and make 
adjustments to the improvement cycles as necessary.  The timeline for meetings began in 
February 2018 through September 2018, with a presentation of team efforts occurring at a clinic 
meeting in November 2018.  
Plan-Do-Study-Act Cycles 
Plan-Do-Study-Act (PDSA) cycles are a common approach of QI teams to produce 
practice improvement that is driven by a change (AHRQ, 2013).  PDSA cycles aim to answer 
three main questions: “What are we trying to accomplish?  How will we know that a change is an 
improvement?  What change can we make that will result in improvement?” (Institute for 
Healthcare Improvement [IHI], 2019).  The IHI (2019) outlines four cyclical steps of the PDSA 
approach.  The first step in the PDSA cycle is Plan, which includes strategizing how tests or 
observations can be used to collect data, stating an objective, predicting intended and unintended 
consequences, and developing a blueprint to test the change.  This portion of the PDSA cycle 
should answer “who, what, where, when, and how.”  The second step is Do, which involves 
trialing the test on a small scale, recording outcomes and observations, and beginning to analyze 
data.  Study is the third step, when members are tasked with completing data analysis, comparing 
actual outcomes to the predicted outcomes, summarizing data, and reflecting on what they 
learned.  Finally, the Act stage involves taking what was learned from the test and making 
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necessary edits to the change.  Figure 1 illustrates the four phases as a sequential process that can 
be repeated to produce multiple cycles in order to drive change. 
Figure 1: PDSA Steps 
 
(IHI, 2019). 
For the Plan phase, the QI team identified CRC screening as the subject of process 
improvement, hypothesized ways to increase screening rates, and proposed an intervention 
aimed at addressing underutilization of Cologuard® in the clinic.  The Do phase of the PDSA 
cycles was an in-person provider education session during the clinic’s Combined Team meeting 
in November 2018, co-led by the primary investigator (PI) of this project and a resident from the 
QI team.  Data analysis occurred during the Study phase.  This project report does not include 
the Act phase. 
Educational Intervention 
The “Clinician’s Reference: Stool-Based Tests for Colorectal Cancer Screening,” (ACS, 
2017a) was selected as a part of the provider-based educational intervention.   The toolkit—
which combines recommendations from the ACS, CDC, and USPSTF—was an optimal solution 
because it is geared toward primary care providers and summarizes the endorsements from 
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several health organizations in a concise, straightforward, and easily presented format.  The 
reference tool features evidence-based facts, recommendations for practice, and comparisons 
among various stool tests.  It focuses on empowering the provider to have a dialogue with 
patients who favor stool-based screening options. 
The first part of the project involved a pre/post-test design to examine primary care 
providers’ knowledge, attitudes, and self-efficacy related to Cologuard®, with the independent 
variable between the pre/post-survey being a provider-based education session.  A co-
presentation with the QI team’s lead resident incorporated an overview of PDSA cycles and the 
clinic’s current procedures for ordering Cologuard®.  Currently, the clinic’s procedure for 
providers ordering Cologuard® includes: provider and patient agree upon Cologuard® as 
screening modality; clinic staff (provider, nurse, or certified surgical technologist [CST]) fills out 
the order sheet; staff faxes order sheet directly to Direct Sciences laboratory; Cologuard® sends 
test kit directly to patient; patient mails sample to lab within 24 hours of collection (if no sample 
is received within 60 days of order date, provider is notified by fax); provider receives test 
results via fax approximately two weeks after sample is received.  This information was 
reviewed using a PowerPoint presentation created by the lead resident.  The Clinician’s 
Reference was then projected onto a screen, and the PI reviewed its content aloud to those in 
attendance at the meeting. 
Sample 
Providers 
Inclusion criteria for this sample included primary care providers (attending physicians, 
resident physicians, and advanced practice providers [APP]) who attended the clinic’s Combined 
Team meeting on November 16, 2018.  Exclusion criteria included involvement in the clinic’s 
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CRC QI team or providers who did not attend the meeting.  Of the 18 primary care providers at 
the meeting, only 14 completed a pre/post-test.  The identity of those 14 providers is anonymous.   
 Medical Records 
A total of 200 medical records were randomly selected from patients who were seen in 
clinic prior to the intervention between August 1, 2018 and October 31, 2018. Another 200 
medical records were randomly selected from patients who were seen in clinic after the 
intervention between December 1, 2018 and February 28, 2019.  Inclusion criteria were: persons 
50 through 75 years of age; attending the primary care clinic only; seen as a Health Maintenance, 
Established Patient, or New Patient visit; seen by a primary care provider who attended 
November’s Combined Team Meeting.  Exclusion criteria included: not average-risk as defined 
by USPSTF; <50 years, >75 years; identified as a duplicate patient; or provider not in attendance 
at interventional November meeting. 
Institutional Review Board Approval 
 An interprofessional training grant was approved by the affiliated university’s 
Institutional Review Board (IRB).  After IRB approval, the QI team was able to begin PDSA 
cycles and an individual project stemming from QI group work began. 
Measures 
 A survey of knowledge, attitudes, and self-efficacy of Cologuard® was created by the PI 
and based on the ACS’s Clinician’s Reference and verbal presentation from the PI and QI lead-
resident (see Appendices A and B).  The survey was distributed to the providers for completion 
at the November meeting.  The survey was the same for both the pre- and post- intervention 
period, and included five knowledge-based questions, five questions about attitudes, and five 
questions about self-efficacy.  Additionally, the post-test included an optional line for comments.  
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The findings of the pre- and post- tests were scored based on correct answers for the knowledge-
based questions (potential range 0-5, highest score = 5), and measured using a Likert scale for 
questions regarding attitudes (potential range 5-25, highest score = 25) and self-efficacy 
(potential range 5-25, highest score = 25). 
Order rates of Cologuard® were collected from 200 randomly-selected charts of patients 
seen in clinic prior to November’s intervention (August 1, 2018 – October 31, 2018), and 200 
randomly-selected charts of patients seen after the intervention (December 1, 2018 – February 
28, 2019) using sample inclusion and exclusion criteria.  The results were stored in a Microsoft 
Excel spreadsheet.  See Table 2 for summary of variables. 
Data Collection 
All study data were kept confidential and stored on the PI’s personal password-protected 
computer with a secure server.  Patient identifiers were not included in data sets.  The first stage 
of data collection included distribution of pre- and post- tests to all 18 providers in attendance at 
the November meeting.  The identity of the participating providers was anonymous.  The 14 
completed surveys were recollected, and paired pre- and post- test responses were then entered 
into Microsoft Excel by the PI.   
The second stage of data collection involved chart reviews of patients who met inclusion 
criteria for the study.  An electronic list was provided by a clinic staff member of all patients 
who met inclusion criteria for the months of August through October 2018.  An online random 
number generator was used to provide 200 random numbers, which correlated to 200 persons on 
the numbered list of patients meeting inclusion criteria for the pre-intervention period.  Of those 
200 charts that were audited, 12 were excluded for the following reasons: provider participated 
on QI team; seen as a nurse visit or in department other than the primary care clinic; past medical 
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history of Crohn’s disease; duplicate patient encounter.  The random number generator was again 
used to provide 12 additional numbers in order to attain a total chart count of 200 patients.  The 
following data for the pre-intervention period were entered into Microsoft Excel: correlating 
chart number; date of service; visit type; provider type; meets screening criteria (Y/N); CRC 
screening up to date (Y/N); colonoscopy ordered/scheduled (Y/N); Cologuard discussed (Y/N); 
Cologuard ordered (Y/N); Notes. 
A similar process was repeated for the post-intervention chart review.  An online number 
generator was again used to generate 200 random numbers that correlated with a numbered list 
of patients meeting inclusion criteria from December 2018 through February 2019.  There were 
23 charts excluded for the following reasons: provider participated on QI team; provider not in 
attendance at interventional meeting; patient less than 50 years of age; patient greater than 75 
years of age.  The online random number generator was used to produce 23 additional numbers.  
200 charts for the post-intervention period were reviewed, and data were entered into Microsoft 
Excel using the same organizational headings from the pre-intervention period.   
Data Analysis 
 Statistical analysis was completed using IBM SPSS statistical software version 24. 
Descriptive analysis was used to determine frequencies with percentages to describe nominal 
demographic variables.  Differences between variables in the samples before and after the 
intervention were assessed using paired sample t-tests to assess changes in attitudes and self-
efficacy, and McNemar’s test for items on knowledge pre/post intervention.  Variances in the 
proportion of Cologuard® ordering rates before and after the intervention were assessed using 
chi-square analyses. 
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Results 
Demographics 
Of the 18 primary care providers in attendance at the meeting, 14 completed pre- and 
post- tests.  The ratio of male to female providers was even.  Half of the providers in attendance 
were resident physicians.  Most of the providers reported less than five years of experience.  See 
Table 3 for provider demographics.   
Provider Knowledge 
 Overall, provider knowledge increased after the educational intervention (see Figure 2).  
The average provider score prior to the education was 3.36 correct responses out of 5 items 
(SD=1.15).  After the intervention, the average provider knowledge score was 4.71 correct 
responses out of 5 items (SD=0.61).  McNemar’s test showed a statistically significant difference 
in knowledge scores before and after the intervention (p<0.001) (see Table 4).  
Provider Attitudes  
 The overall means score of provider attitudes increased from 19.41 out of a possible 25 
points (SD=3.11) before the intervention to 20.64 out of a possible 25 points (SD=1.74) after the 
intervention.  Though there was an increase in positive attitudes relating to Cologuard®, 
statistical analyses revealed that a change in provider attitudes pre- and post- intervention was 
not statistically significant (p=0.142) (see Table 4 and Figure 3). 
Provider Self-Efficacy 
 Provider self-efficacy related to Cologuard® increased after the educational intervention.  
The overall mean for provider self-efficacy increased from 19.07 out of a possible 25 points in 
the pre-intervention period (SD=4.67) to a mean of 23.29 out of a possible 25 points in the post-
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intervention period (SD=1.98).  Thus, the change in self-efficacy from the pre- to post- test was 
statistically significant (p=0.002) (see Table 4 and Figure 4). 
Order Rates of Cologuard® 
 Pre-Intervention  
The PI performed a chart review of 200 randomly selected patients who met all inclusion 
criteria and for whom screening was indicated during the pre-intervention months of August 
through October 2018.  Of those 200 patients, 151 (75.5%) had documentation in at least one 
place in the Electronic Health Record (EHR) of up-to-date CRC screening.  The remaining 49 of 
200 patients (24.5%) did not have documentation in the EHR to indicate CRC screening was 
current.   
Of the 49 patients who were not up-to-date on screening, 31 (63.3%) did not have CRC 
screening ordered during the patient-provider encounter.  Reasons for not ordering some 
modality of CRC screening included: patient refused, provider will discuss at subsequent visit, or 
no reason documented in EHR.  Of the 49 patients without previously documented CRC 
screening, 18 (36.7%) had CRC screening ordered at the time of their clinic visit.   
Of the 18 patients who had CRC screening orders placed during the pre-intervention 
period, 17 (94.4%) had colonoscopy orders placed, and Cologuard® was ordered for one patient 
(5.6%).  See Figure 5 for comparison of order rates pre- and post- intervention. 
Post-Intervention 
The PI performed a chart review from 200 randomly selected patients who met all 
inclusion criteria and for whom screening was indicated during the post-intervention months of 
December 2018 through February 2019.  Of those 200 patients, 142 (71%) had documentation in 
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at least one place in the EHR of up-to-date CRC screening.  The remaining 58 of 200 patients 
(29%) did not have documentation in the EHR to indicate CRC screening was current.   
Of the 58 patients who were not up-to-date on screening, 26 (44.8%) did not have CRC 
screening ordered during the patient-provider encounter.  Reasons for not ordering some 
modality of CRC screening included: patient refused, provider will discuss at subsequent visit, or 
no reason documented in EHR.  Of the 58 patients without previously documented CRC 
screening, 32 (55.2 %) had CRC screening ordered at the time of their clinic visit.   
Of the 32 patients who had CRC screening orders placed during the post-intervention 
period, 27 (84.3%) had colonoscopy orders placed, 3 (9.4%) had fecal occult blood test (FOBT) 
ordered, and 2 (6.3%) had Cologuard® ordered.  See Figure 5 for comparison of order rates pre- 
and post- intervention. 
Finally, a chi-square test was used to analyze Cologuard® order rates for patients who 
were not up-to-date on CRC screening in the pre- and post- intervention periods.   Analyses 
revealed 𝑥2=0.193 and no statistically significant difference in Cologuard® order rates (p=0.660) 
from the pre- to post- intervention periods (see Table 5).  
Barriers Identified 
At the end of the post-test, providers were asked to leave additional comments explaining 
their answer.  In doing so, the PI hoped to gain insight to potential barriers of Cologuard® use in 
practice and identify potential solutions moving forward.  Eight out of 14 providers left 
comments.  
Five providers commented there is no specific place to document Cologuard® within the 
EHR.  Furthermore, many of these providers added there is no consistent place populated within 
the EHR to see if screening was completed or what the results were.  Solutions to these barriers 
3 
EFFECT OF EDUCATIONAL PROGRAM RELATED TO COLOGUARD®  
2 
 
included provider comments such as “create EHR result field for Cologuard” ; “in patient 
flowsheet where we document mammogram, eye exam, etc. make a column for Cologuard so it 
can easily be seen whether they have had it and when” ; “make a consistent location under same 
heading as colonoscopy.” 
The following remarks represent perceived barriers of Cologuard® from providers in this 
clinic: “the form is a natural barrier like any paperwork in clinic” ; “time to complete order form 
– improving with my new CST as she is more involved” ; “a handout would help for patients 
literate enough, like main points on a card.”    
Discussion  
Influencing Knowledge, Attitudes, Self-Efficacy, and Order Rates 
 The use of a QI team is an effective way to identify problems within a setting, gain 
perspective from different disciplines, hypothesize potential solutions, and plan and execute 
practice improvement cycles with the aim of achieving a goal set by the QI group.  In both 
collaborative and individual efforts, the QI group and PI at a large primary care clinic sought to 
improve variables related to Cologuard®, including provider knowledge, attitudes, self-efficacy, 
and order rates of Cologuard®. 
A provider-based educational intervention improved provider knowledge and self-
efficacy related to Cologuard® use in clinic.  The intervention did not, however, change attitudes 
toward Cologuard® during the time period identified for this study.  Though the overall mean for 
attitudes increased, the change was not statistically significant.  Provider order rates of 
Cologuard® did not increase after the educational intervention. 
The outcomes of this experiment are similar to other studies in the literature.  Sheinfeld-
Gorin et al. (2000) used a similar pre- and post- test design with an educational intervention.  
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The study concluded that there was a statistically significant difference in provider knowledge 
scores before and after the educational intervention (p<0.001).  Additionally, barriers were 
identified and included in the discussion of the study (Sheinfeld-Gorin et al., 2000).   
The study by Rim et al. (2009) revealed a strong association between provider knowledge 
and higher CRC screening rates (p=0.02), but no statistically significant correlation between 
attitudes, beliefs, and CRC screening practices.  The results of the PI’s study do not take into 
account overall screening rates in the pre- to post- intervention period.  It would be interesting, 
however, to examine whether the findings of Rim et al. could be generalized by looking at 
overall screening (beyond just Cologuard®) in the PI’s primary care clinic. 
Application of Theory 
 This study supports the use of the TRA/TPB framework.  One of the measures examined 
in the pre- and post- surveys was provider attitudes.  Based on this theoretical framework, if an 
increase in attitudes will increase the likelihood of a behavior, then one can assume an increase 
in provider attitudes will lead to increased CRC screening by providers.  It is important to note 
there was an increase in positive attitudes relating to Cologuard®, although it was not 
statistically significant (see Figure 3).   The second concept of the TRA/TPB framework is 
subjective norms.  This aspect is applicable because referent groups often share a commonality; 
the shared sample demographic was profession (primary care providers).  In accordance to the 
TRA/TPB theory, a provider will be more likely to screen for CRC if he or she feels that his or 
her referent groups also support, utilize, and value CRC screening.  Self-efficacy ties closely 
with behavioral control—or assumed ease versus difficulty of a behavior.  This study revealed a 
statistically significant change in provider self-efficacy related to Cologuard® in the pre- and 
post- intervention periods.  
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Implications for Practice  
Providers who offered written feedback after the intervention and post-test allowed for 
identification of barriers and possible solutions.  One way to integrate results of this study into 
practice is to consider adding a clear, logical, and pre-populated field within the EHR to address 
Cologuard® orders and results.  This step may alleviate or eliminate the provider from having to 
involve the nurse or CST in completing the paper order form, waiting for a fax or notification not 
otherwise tasked to the provider, or searching through the EHR to find if and when Cologuard® 
was completed.   
Another implication for future practice includes the use of a provider portal as a means to 
potentially increase order rates and overall satisfaction with the ordering and result retrieval 
processes.  Through the Cologuard® website, institutions can create an online portal for placing 
orders and reviewing results.  Utilizing the provider portal could potentially address the issue of 
paper forms identified as a barrier by providers in this study.  Orders placed electronically will 
be automatically uploaded onto the portal, and faxed order requests—this clinic’s current 
procedure for ordering Cologuard®—will deliver results via both fax and online portal 
(Cologuard, 2018).  Confirmation of orders and results are stored within the portal and can be 
easily accessed for a particular patient, reducing the need for providers to search the EHR or 
faxed results for this information.   
Patient-based interventions could also address underutilization of Cologuard® for 
patients preferring non-invasive CRC screening.  Examples of interventions that educate and 
empower the patient, rather than the provider, include: written materials (i.e. pamphlets, posters, 
or patient handouts), and providing the patient with access to health information on the internet 
(i.e. Cologuard® website or other evidence-based sites).   
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It is worthwhile to note the potential impact of provider-based interventions on certain 
measures.  Because a statistically significant change was seen in provider knowledge and self-
efficacy of Cologuard® in the post-intervention period, it may be beneficial to conduct 
educational sessions on other topics, such as various MACRA measures or weaker areas of 
practice, to boost knowledge, self-efficacy, and possibly provider attitudes towards those 
matters.   
Implications for Further Study 
 The need to determine the reliability and validity of the provider survey is one important 
implication for further study, as the true reliability and validity remains unknown; if this cannot 
be achieved, consideration of a different validated survey may be warranted.  It may also be 
useful to extend the time frame of the study to determine whether knowledge, attitudes, and self-
efficacy were sustained over time.  Finally, a multi-site design would be ideal to test replicability 
and generalizability of the study.  
Limitations  
 Limitations of this study include a small sample size of providers (n=14) from which 
demographics, knowledge, attitudes, and self-efficacy were examined.  A larger sample size 
would have been more ideal in order to measure more accurate variances in measures pre- and 
post- intervention.  This was a single-center design over the course of a few months.  Increasing 
the project to a multi-center study for a longer amount of time may help to generalize and 
compare outcomes.  The reliability and validity of the pre- and post- test has not been 
determined, as it was generated by the PI and not trialed prior to this study.  Additionally, data 
collected from the pre- and post- tests involve answers which may reflect responder bias. 
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Additional limitations include small sample sizes in both the pre- and post- intervention 
chart review phases.   Although 200 charts were reviewed in both the pre- and post- periods, 151 
out of 200 patients were up-to-date on screening recommendations in the pre-intervention phase.  
This left only 49 out of 200 patients needing CRC screening.  Similarly in the chart review for 
patients seen after the intervention, only 58 patients did not have documentation of current CRC 
screening.   
Conclusion 
CRC is the third most prevalent cancer and second deadliest cancer in the U.S., with 
higher incidences in Kentucky than the majority of other states (CDC, 2017).  Because most 
colorectal malignancies are slow-growing, CRC screening is vital in decreasing morbidity and 
mortality.  Although CRC prevention tests—such as colonoscopy or flexible sigmoidoscopy—
are the preferred screening modality, Cologuard® is a safe, non-invasive, and highly sensitive 
option for patients preferring stool-based screening tests (ACS, 2017a).  
Quality improvement groups can be instrumental in identifying a problem in practice and 
working with various disciplines to improve upon that problem.  In this study, a provider-based 
intervention stemming from both group and individual contributions was chosen to address the 
underutilization of Cologuard® in clinic.  Presentation to clinic providers using the ACS’s 
Clinician’s Reference and an overview of the clinic’s current procedures for ordering 
Cologuard® was chosen as the provider-based intervention.  Pre- and post- tests revealed a 
statistically significant increase in provider knowledge and self-efficacy after the intervention. 
While differences in provider attitudes and order rates of Cologuard were not statistically 
significant, it is important to consider other implications for future practice, such as 
modifications to the EHR or use of Cologuard® portal, to increase those measures.  This 
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initiative may provide necessary suggestions and first-steps to facilitate organizational changes 
that would lead to an increase in Cologuard® orders. 
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Appendix A. Pre-test of Knowledge, Attitudes, and Self-Efficacy Related to Cologuard 
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Appendix B. Post-test of Knowledge, Attitudes, and Self-Efficacy Related to Cologuard 
 
 
32 
EFFECT OF EDUCATIONAL PROGRAM RELATED TO COLOGUARD®  
2 
 
 
33
EFFECT OF EDUCATIONAL PROGRAM RELATED TO COLOGUARD®  
3 
 
Table 1. Recommendations for Common CRC Screening Modalities 
Screening Modality Screening Interval 
(Negative result) 
CRC Prevention Test  
 Colonoscopy 
 Flexible sigmoidoscopy 
 CT colonography 
 
Every 10 years 
Every 5 years 
Every 5 years 
CRC Detection Test (Non-Invasive) 
 High-sensitivity FIT test (several brands) 
 High-sensitivity guaiac-based fecal occult blood test 
(Hemoccult Sensa) 
 FIT-DNA test (Cologuard®) 
 
Yearly 
 
Yearly 
 
Every 3 years 
 
(Rex et al., 2017) 
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Table 2. Summary of Variables 
 
Variable Scoring Measure 
Time-point of 
Measure 
Level of 
Measure 
Data Source 
Knowledge of 
Cologuard® 
1-5 based on # 
correct 
Pre and Post 
Interval Survey 
Attitudes about 
Cologuard® 
Likert scale Pre and Post 
Interval Survey 
Provider self-
efficacy 
Likert scale Pre and Post 
Interval Survey 
Cologuard® orders Yes vs. No Pre and Post 
Nominal Electronic 
Health Record 
 
 
Variable Scoring measure Timeline Level of Measure 
Gender  Male vs Female Baseline Nominal 
Type of Provider 
Attending Physician 
Resident Physician  
APP (Nurse Practitioner or 
Physician’s Assistant)  
Baseline 
Nominal 
Experience of Provider <5 years vs >5 years Baseline Nominal 
Employment status Full vs Part Baseline Nominal 
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Table 3. Summary of Provider Demographics 
 
 n n(%) 
Providers in attendance 18 100% 
Surveys completed 14 77.8% 
 
Category n n(%) 
Gender: 
      Male  
      Female 
      Did not specify  
 
6 
6 
2 
 
42.9% 
42.9% 
14.2% 
Type of Provider: 
      Attending 
      Resident 
      APP 
      Did not specify 
 
5 
7 
2 
0 
 
35.7% 
50.0% 
14.3% 
0.0% 
Years of 
Experience: 
      <5 years 
      >5 years 
      Did not specify 
 
 
8 
1 
5 
 
 
57.1% 
7.1% 
35.7% 
Employment Status: 
      Full-time 
      Part-time 
      Did not specify 
 
9 
0 
5 
 
64.3% 
0.0% 
35.7% 
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Table 4. Statistical Analyses of Provider Knowledge, Attitudes, and Self-Efficacy 
 
 Potential range Pre-education 
Mean (SD) 
Post-education 
Mean (SD) 
P-value 
Knowledge 0-5 3.36 (1.15) 4.71 (0.61) <0.001 * 
Attitudes 5-25 19.41 (3.11) 20.64 (1.74) 0.142 
Self-efficacy 5-25 19.07 (4.67) 23.29 (1.98) 0.002 * 
 
* denotes statistically significant data based on p-value <0.05 
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Table 5. Statistical Analyses of Cologuard® Orders for Patients Not Up-To-Date with CRC 
Screening 
 
 Cologuard® 
ordered: YES 
Cologuard® 
ordered: NO 
Row Totals 
Pre-Intervention 1 
(1.37) [1.10] 
48 
(47.63) [0.00] 
49 
Post-Intervention 2 
(1.63) [0.09] 
56 
(56.37) [0.00] 
58 
Column Totals 3 104 107 (Grand Total) 
𝑥2 = 0.193 
P-value = 0.660 
The result is not significant at p < 0.05.  
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Figure 2. Percentage of Knowledge Questions Answered Correctly 
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Figure 3. Measurement of Provider Attitudes 
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Figure 4. Measurement of Provider Self-Efficacy 
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Figure 5. Comparison of Cologuard® Order Rates Pre- and Post- Intervention 
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